الإحصائيات الأساسية
| LEI | 549300EOYCQ8SW3NVE64 |
| CIK | 1326190 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Altimmune, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32587 ALTIMMUNE, |
|
| August 12, 2025 |
Exhibit 99.1 Altimmune Announces Second Quarter 2025 Financial Results and Business Update Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ALTIMMUNE, INC. |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 26, 2025 |
Exhibit 99.2 IMPACT Phase 2b MASH Trial - Topline Results Pemvidutide: Designed to be the Treatment of Choice for Liver and Cardiometabolic Diseases J u n e 2 6 , 2 0 2 5 Company Confidential Forward-looking statements Safe-Harbor Statement This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” with |
|
| June 26, 2025 |
Exhibit 99.1 Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement |
|
| May 13, 2025 |
Exhibit 99.2 Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutide GAITHERSBURG, MD – May 13, 2025 – Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic d |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 ALTIMMUNE, INC. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 13, 2025 |
Exhibit 99.1 Altimmune Announces First Quarter 2025 Financial Results and Business Update Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term invest |
|
| May 13, 2025 |
Exhibit 10.3 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of May 13, 2025 and is entered into by and among Altimmune, Inc., a De |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 11, 2025 |
Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 March 11, 2025 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Altimmune, Inc.: Registration Statement on Form S-3, filed February 27, 2025 (File No. 333- 285355) Ladies and Gentlemen: Pursuant to Rule 461 under t |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Consulting Agreement, dated February 6, 2025, by and between Altimmune, Inc. and Catherine Sohn Exhibit 10.15 ALTIMMUNE, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is hereby made and entered into as of January 15, 2025 (the “Effective Date”), by and between Altimmune, Inc. and its Affiliates, a Delaware corporation (“Altimmune”), having a place of business at 910 Clopper Road, Suite 201- S, Gaithersburg, Maryland 20878 and Catherine Sohn (“Consultant”). 1.Engagemen |
|
| February 27, 2025 |
Description of Registrant’s Securities Exhibit 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Altimmune, Inc. (“Altimmune” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restate |
|
| February 27, 2025 |
Exhibit 1.2 ALTIMMUNE, INC. EQUITY DISTRIBUTION AGREEMENT February 27, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 PIPER SANDLER & CO. 1251 Avenue of the Americas, 39th Floor New York, New York 10020 STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 7th Avenue, 11th Floor New York, New York 10019 Ladies and Gentlemen: As further set forth in this agreement |
|
| February 27, 2025 |
Altimmune, Inc. Non-Employee Director Compensation Policy Exhibit 10.7 ALTIMMUNE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Director Compensation Policy of Altimmune, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpose stated a |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32 |
|
| February 27, 2025 |
Exhibit 21 SIGNIFICANT SUBSIDIARIES List of Subsidiaries Jurisdiction of Incorporation or Organization Altimmune, LLC (1) Delaware Altimmune UK, Limited (1) United Kingdom Spitfire Pharma, LLC (1) Delaware Altimmune AU Pty, Limited (1) Australia (1) Wholly owned subsidiary of the Company |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate (5) Amount of Registration |
|
| February 27, 2025 |
Exhibit 99.1 Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 |
|
| February 27, 2025 |
Insider Trading Policies and Procedures Exhibit 19 ALTIMMUNE, INC. AMENDED AND RESTATED INSIDER TRADING POLICY Altimmune, Inc. (the “Company”) has adopted the following amended and restated policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the sev |
|
| February 27, 2025 |
Consent of Goodwin Procter LLP (included in Exhibit 5.1) Exhibit 5.1 Goodwin Procter llp 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 February 27, 2025 Altimmune, Inc. 910 Clopper Road Suite 201S, Gaithersburg, MD 20878 Re: Securities Being Registered under Registration Statement on Form S-3 We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-3 (as amended or supplemented, the “Regi |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 ALTIMMUNE, INC. |
|
| February 27, 2025 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.5 ALTIMMUNE INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ], 2025 Subordinated Debt Securities TABLE OF CONTENTS! ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee's Certificate 6 Secti |
|
| February 27, 2025 |
EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par |
|
| February 27, 2025 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.4 Altimmune Inc. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ], 2025 Senior Debt Securities TABLE OF CONTENTS! ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.0I Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee's Certificate 6 Section 2.03 |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 ALTIMMUNE, INC. |
|
| February 25, 2025 |
Exhibit 99.1 Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver dis |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 ALTIMMUNE, INC. |
|
| November 14, 2024 |
EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Non-US Institution – TAM UK International Holdings Limited, a private limited company incorporated in England and Wales, is a holding company and parent entity to Threadneedle Holdings Limited. Non-US Institut |
|
| November 14, 2024 |
to Schedule 13G Powers of Attorney LIMITED POWER OF ATTORNEY EX-99.III Exhibit III to Schedule 13G Powers of Attorney LIMITED POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, which are intended to constitute a Limited Power of Attorney, that TAM UK International Holdings Limited, a company incorporated under the laws of England and Wales under registered number 12728685, with its principal place of business at Cannon Place, 78 Cannon Street, London, EC4N 6 |
|
| November 14, 2024 |
ALT / Altimmune, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Altimmune, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| November 14, 2024 |
to Schedule 13G Joint Filing Agreement EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated November 14, 2024 in connection with their beneficial ownership of Altimmune, Inc. Each of TAM UK International Holdings Limited, Threadneedle Holdings Limited, TAM UK Holdings Limited, Threadneedle Asset Management Holdings Limited, TC |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 ALTIMMUNE, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 12, 2024 |
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer Exhibit 99.1 Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer GAITHERSBURG, MD – November 11, 2024 – Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company’s finance and accounting functions, including S |
|
| November 12, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of November 6, 2024, by and between Greg Weaver (“Executive”) and Altimmune, Inc., a Delaware corporation (“Altimmune”). WHEREAS, the Board of Directors of Altimmune (the “Board”) desires to employ Executive, and Executive desires to be employed by Altimmune pursuant to the terms and conditions se |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 ALTIMMUNE, INC. |
|
| November 12, 2024 |
Exhibit 99.1 Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applica |
|
| October 17, 2024 |
ALT / Altimmune, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 AltimmuneInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALTIMMUNE INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 02155H200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 16, 2024 |
ALT / Altimmune, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ALTIMMUNE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 02155H200 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule p |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 ALTIMMUNE, INC. |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 ALTIMMUNE, INC. |
|
| August 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ALTIMMUNE, INC. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 8, 2024 |
Exhibit 99.1 Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 C |
|
| June 26, 2024 |
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt Exhibit 99.1 Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt GAITHERSBURG, MD – June 26, 2024 – Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Company’s Chief Financial Officer, passed away unexpectedly on Monday, June 24, 2024. “We are all shocked and saddened by Rich’s passing. On behalf of everyone |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 ALTIMMUNE, INC. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ALTIMMUNE, INC. |
|
| May 9, 2024 |
Exhibit 99.1 Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32 |
|
| March 27, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 ALTIMMUNE, INC. COMPENSATION RECOVERY POLICY Adopted as of September 28, 2023 Altimmune, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below |
|
| March 27, 2024 |
Description of Registrant’s Securities Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Altimmune, Inc. (“Altimmune” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restate |
|
| March 27, 2024 |
Exhibit 99.1 Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week da |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 ALTIMMUNE, INC. |
|
| March 27, 2024 |
Exhibit 21 SIGNIFICANT SUBSIDIARIES List of Subsidiaries Jurisdiction of Incorporation or Organization Altimmune, LLC (1) Delaware Altimmune UK, Limited (1) United Kingdom Spitfire Pharma, LLC (1) Delaware Altimmune AU Pty, Limited (1) Australia (1) Wholly owned subsidiary of the Company |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par |
|
| March 5, 2024 |
ALT / Altimmune, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALTIMMUNE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 02155H200 (CUSIP Number) FEBRUARY 26, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 14, 2024 |
ALT / Altimmune, Inc. / AMERIPRISE FINANCIAL INC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: This Sched |
|
| February 14, 2024 |
ALT / Altimmune, Inc. / TEACHERS ADVISORS, LLC Passive Investment CUSIP No. 02155H200 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2024 |
ALT / Altimmune, Inc. / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
to Schedule 13G Powers of Attorney LIMITED POWER OF ATTORNEY EX-99.III 4 d774900dex99iii.htm EX-99.III Exhibit III to Schedule 13G Powers of Attorney LIMITED POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, which are intended to constitute a Limited Power of Attorney, that TAM UK International Holdings Limited, a company incorporated under the laws of England and Wales under registered number 12728685, with its principal place of business at Cannon Place, |
|
| February 14, 2024 |
ALT / Altimmune, Inc. / Nuveen Asset Management, LLC Passive Investment CUSIP No. 02155H200 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2024 |
ALT / Altimmune, Inc. / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 c108110sc13ga.htm CUSIP No. 02155H200 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2024 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d774900dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2024 in connection with their beneficial ownership of Altimmune, Inc. Each of TAM UK International Holdings Limited, Threadneedle Holdings Limited, TAM UK Holdings Limited, Threadneedle Asset M |
|
| February 14, 2024 |
ALT / Altimmune, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Non-US Institution – TAM UK International Holdings Limited, a private limited company incorporated in England and Wales, is a holding company and parent entity to Threadneedle Holdings Limited. Non-US Institut |
|
| February 13, 2024 |
ALT / Altimmune, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Altimmune Inc Title of Class of Securities: Common Stock CUSIP Number: 02155H200 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| November 30, 2023 |
Exhibit 99.1 Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide ● Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatment ● Over 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks ● Robust reductions in BMI and serum lipids and improvements in blood |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 ALTIMMUNE, INC. |
|
| November 30, 2023 |
Exhibit 99.2 MOMENTUM—Pemvidutide Phase 2 Obesity Trial Topline Week 48 Results NASDAQ: ALT 30 November 2023 Forward-looking statements Safe-Harbor Statement This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 ALTIMMUNE, INC. |
|
| November 7, 2023 |
Exhibit 99.1 Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcellTM in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be he |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 ALTIMMUNE, INC. |
|
| August 16, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALTIMMUNE, INC. |
|
| August 10, 2023 |
Exhibit 99.1 Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment in IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcellTM in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be h |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ALTIMMUNE, INC. |
|
| May 11, 2023 |
Exhibit 99.1 Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Top-line results from the Phase 2 trial of HepTcellTM in chronic hepatitis B (CHB) expected Q1 2024 Webc |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| April 12, 2023 |
ALT / Altimmune Inc / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment CUSIP No. 02155H200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* ALTIMMUNE INC. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| March 27, 2023 |
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors Exhibit 99.1 Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors GAITHERSBURG, Maryland, March 27, 2023 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. “We are delighted to welcome Catherine to our Board of Directors”, said Vipin K |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 ALTIMMUNE, INC. |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 ALTIMMUNE, INC. |
|
| March 21, 2023 |
Exhibit 99.2 MOMENTUM—Pemvidutide Phase 2 Obesity Trial Week 24 Interim Analysis NASDAQ: ALT M. Scott Harris, MD, Chief Medical Officer Louis Aronne, MD, Principal Investigator Sanford I. Weill Professor of Metabolic Research Professor of Clinical Medicine, Weill Cornell Medicine 21 March 2023 Forward-looking statements Safe-Harbor Statement This presentation has been prepared by Altimmune, Inc. ( |
|
| March 21, 2023 |
Exhibit 99.1 Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis of 160 Subjects) ● Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24 ● Mean weight loss of 11.9% (placebo-adjusted 11.1%) in subjects weighin |
|
| February 28, 2023 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.4 Altimmune Inc. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ], 2023 Senior Debt Securities TABLE OF CONTENTS! ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.0I Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee's Certificate 6 Section 2.03 |
|
| February 28, 2023 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.5 ALTIMMUNE INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ], 2023 Subordinated Debt Securities TABLE OF CONTENTS! ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee's Certificate 6 Secti |
|
| February 28, 2023 |
Exhibit 10.30 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of January 1, 2023, by and between Raymond Jordt (“Jordt”) and Altimmune, Inc., a Delaware corporation (“Altimmune” or the “Company”). WHEREAS, the Board of Directors of Altimmune (the “Board”) desires to employ Jordt, and Jordt desires to be employed by Altimmune pursuant to the terms and condit |
|
| February 28, 2023 |
Description of Registrant’s Securities Exhibit 4.10 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Altimmune, Inc. (“Altimmune” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restat |
|
| February 28, 2023 |
Exhibit 99.1 Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial expected mid-2023 Webcast to be held today, February 28, 2023, at 8:30 am ET GAITHERSBURG, Maryland - February 28, 2023 - Altimmune, Inc. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
Exhibit 21 SIGNIFICANT SUBSIDIARIES List of Subsidiaries Jurisdiction of Incorporation or Organization Altimmune, LLC (1) Delaware Altimmune UK, Limited (1) United Kingdom Spitfire Pharma, LLC (1) Delaware Altimmune AU Pty, Limited (1) Australia (1) Wholly owned subsidiary of the Company |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate (5) Amount of Registration Fee (5) |
|
| February 28, 2023 |
EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par |
|
| February 28, 2023 |
Altimmune, Inc. Non-Employee Director Compensation Policy Exhibit 10.7 ALTIMMUNE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Director Compensation Policy of Altimmune, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpose stated a |
|
| February 28, 2023 |
Exhibit 1.2 ALTIMMUNE, INC. EQUITY DISTRIBUTION AGREEMENT February 28, 2023 EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 JMP SECURITIES LLC 600 Montgomery Street, Suite 1100 San Francisco, California 94111 B. RILEY SECURITIES, INC. 299 Park Avenue, 21st Floor New York, New York 10171 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Altimmune, I |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 ALTIMMUNE, INC. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32 |
|
| February 14, 2023 |
ALT / Altimmune Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d912790213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Altimmune Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 14, 2023 |
ALT / Altimmune Inc / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 c105522sc13ga.htm CUSIP No. 02155H200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* ALTIMMUNE INC. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 14, 2023 |
ALT / Altimmune Inc / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2023 |
ALT / Altimmune Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 alt28230sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Altimmune, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the approp |
|
| February 9, 2023 |
ALT / Altimmune Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Altimmune Inc. Title of Class of Securities: Common Stock CUSIP Number: 02155H200 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d |
|
| December 20, 2022 |
Exhibit 99.1 Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) ? ? Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeks ? Significant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1) observed, both established m |
|
| December 20, 2022 |
Exhibit 99.2 A 24 - Week (12 - Week Extension) Trial of Pemvidutide in Subjects with Non - alcoholic Fatty Liver Disease (NAFLD) NASDAQ: ALT Stephen Harrison, MD, Lead Investigator 20 December 2022 Forward - looking statements Safe - Harbor Statement This presentation has been prepared by Altimmune, Inc .. ("we," "us," "our," "Altimmune" or the "Company") and includes certain ?forward - looking st |
|
| December 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 ALTIMMUNE, INC. |
|
| November 10, 2022 |
Exhibit 99.1 Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected Q1 2023 GAITHERSBURG, Maryland - November 10, 2022 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage bi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 ALTIMMUNE, INC. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 29, 2022 |
Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 ALTIMMUNE, INC. |
|
| September 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 ALTIMMUNE, INC. |
|
| September 14, 2022 |
Exhibit 99.2 12 - Week, Phase 1b Study of Pemvidutide in Overweight and Obese Subjects with Non - Alcoholic Fatty Liver Disease (NAFLD) ? Topline Results NASDAQ: ALT Stephen Harrison, MD, Lead Investigator 14 September 2022 Forward - looking statements Safe - Harbor Statement This presentation has been prepared by Altimmune , Inc .. ("we," "us," "our," " Altimmune " or the "Company") and includes |
|
| September 14, 2022 |
Exhibit 99.1 Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD ? ? All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions in liver fat, with a 68.5% relative reduction in liver fat content in subjects receiving 1.8 mg dose at 12 |
|
| August 16, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 ALTIMMUNE, INC. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2022 |
Exhibit 99.1 Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update ? Topline data from 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected mid-September 2022 ? ? GAITHERSBURG, MD, - August 11, 2022 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial re |
|
| July 7, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 7, 2022, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the ?Filers?). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or |
|
| July 7, 2022 |
ALT / Altimmune Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) June 27, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| May 12, 2022 |
Exhibit 99.1 Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update ? Multiple clinical trial data readouts expected in Q3 and Q4 2022 ? ? GAITHERSBURG, MD, - May 12, 2022 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. ? ?We co |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 ALTIMMUNE, INC. |
|
| March 24, 2022 |
ALT / Altimmune Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 24, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Altimmune, Inc. and further agree to the filing of this Joint Filing Agreement as an exhibi |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ? Commission File Number: 001-32587 ALTIMM |
|
| March 15, 2022 |
Exhibit 99.1 Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update ? Data readouts from multiple clinical trials expected during the next 6 to 12 months ? Strong cash position of $190.3 million as of December 31, 2021 ? ? GAITHERSBURG, MD, - March 15, 2022 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced fi |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 ALTIMMUNE, INC. |
|
| March 15, 2022 |
Description of Registrant’s Securities Exhibit 4.10 ? Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended ? The summary of the general terms and provisions of the registered securities of Altimmune, Inc. (?Altimmune? ?we,? or ?our?) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Re |
|
| March 15, 2022 |
Exhibit 21 SIGNIFICANT SUBSIDIARIES ? List of Subsidiaries ? Jurisdiction of Incorporation or Organization Altimmune, LLC (1) ? Delaware Altimmune UK, Limited (1) ? United Kingdom Spitfire Pharma, LLC (1) ? Delaware Altimmune AU Pty, Limited (1) ? Australia (1) Wholly owned subsidiary of the Company |
|
| March 15, 2022 |
EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par |
|
| February 14, 2022 |
ALT / Altimmune Inc / SPHERA FUNDS MANAGEMENT LTD. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Altimmune, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? |
|
| February 14, 2022 |
ALT / Altimmune Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 14, 2022 |
ALT / Altimmune Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Altimmune, Inc. |
|
| February 11, 2022 |
PLCE / Children's Place Inc / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment CUSIP No. 168905107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.)* ALTIMMUNE INC. (Name of Issuer) Common (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 11, 2022 |
PLCE / Children's Place Inc / TEACHERS ADVISORS, LLC Passive Investment CUSIP No. 168905107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.)* ALTIMMUNE INC. (Name of Issuer) Common (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 3, 2022 |
ALT / Altimmune Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 17, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2021 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File |
|
| December 13, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into as of December 10, 2021, by and between Richard I. Eisenstadt (?Eisenstadt?) and Altimmune, Inc., a Delaware corporation (?Altimmune?). WHEREAS, the Board of Directors of Altimmune (the ?Board?) desires to employ Eisenstadt, and Eisenstadt desires to be employed by Altimmune pursuant to the terms and |
|
| December 13, 2021 |
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer Exhibit 99.1 Altimmune Appoints Richard Eisenstadt as Chief Financial Officer GAITHERSBURG, MD, - December 13, 2021 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. Mr. Eisenstadt succeeds Will Bro |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2021 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 9, 2021 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT PAGE OF PAGES 14 2. AMENDMENT/MODIFICATION NO.5. PROJECT NO. (If applicable) P00008 6. ISSUED BY CODE 7. ADMINISTERED BY (If other than Item 6) COD |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 ALTIMMUNE, INC. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2021 |
Exhibit 99.1 Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update ? Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment ? Approximately $200 Million in cash and short-term investments to advance pipeline ? ? GAITHERSBURG, |
|
| September 28, 2021 |
Exhibit 99.1 Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers ? Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dose ? Pemvidutide was well-tolerated without the need for dose titration ? No discontinuations due to treatment-emergent adverse events ? NASH IND has cleared FDA review; 12-week NAFLD st |
|
| September 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 ALTIMMUNE, INC. |
|
| September 24, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 ALTIMMUNE, INC. |
|
| August 31, 2021 |
Joint Filing Agreement by and among the Reporting Persons, dated as of August 31, 2021. Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Altimmune, Inc. |
|
| August 31, 2021 |
ALT / Altimmune Inc / SPHERA FUNDS MANAGEMENT LTD. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Altimmune, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 02155H200 (CUSIP Number) August 26, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Ru |
|
| August 16, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 ALTIMMUNE, INC. |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2021 |
Exhibit 99.1 Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update ? 12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September ? Approximately $218 Million in Cash and Short-Term Investments to Advance Obesity and Liver Disease Pipeline ? ? GAITHERSBURG, MD, - August 10, 2021 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutica |
|
| August 10, 2021 |
? Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT PAGE OF PAGES 13 2. AMENDMENT/MODIFICATION NO.5. PROJECT NO. (If applicable) P00007 6. ISSUED BY CODE 7. ADMINISTERED BY (If other than Item 6) C |
|
| June 29, 2021 |
Altimmune Announces Update on AdCOVIDTM Phase 1 Clinical Trial Exhibit 99.1 Altimmune Announces Update on AdCOVIDTM Phase 1 Clinical Trial ? AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers ? Altimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programs ? Altimmune also provides an update on its T-COVIDTM Phase 1/2 Clinical Trial GAITHERSBURG, MD ? |
|
| June 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2021 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 16, 2021 |
Exhibit 99.1 Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers ? Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment target ? Ascending multi-dose regimen well-tolerated without necessity for dose titration ? Trial continuing with 12-week data expected in Q3 2021 ? Compa |
|
| June 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2021 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 17, 2021 |
First Quarter 2021 Results Corporate Update & Financial Results May 17, 2021 NASDAQ: ALT EX-99.2 3 alt-ex992100.htm EX-99.2 First Quarter 2021 Results Corporate Update & Financial Results May 17, 2021 NASDAQ: ALT 2 Forward-looking statements Safe-Harbor Statement This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 ALTIMMUNE, |
|
| May 17, 2021 |
Statement of Work, dated March 9, 2021, by and between Altimmune, Inc. and Lonza Houston Inc. Exhibit 10.2 Confidential Treatment Requested ? Certain Portions of this Exhibit, Marked as [***], Have Been Omitted Pursuant to a Pending Request for Confidential Treatment and Have Been Filed Separately with the Securities and Exchange Commission Statement of Work This Statement of Work SOW A-04 (this "SOW") is effective as of March 8, 2021 (the "Effective Date") and is agreed to by Altimmune In |
|
| May 17, 2021 |
Exhibit 10.1 AMENDMENT NO. 6 TO SECOND RESTATED LICENSE AGREEMENT This Amendment No. 6 (?Amendment No. 6?) to the Second Restated License Agreement is made and entered into on the date of the last signature below by and between: Janssen Vaccines & Prevention B.V., a company under Dutch law with limited liability, with registered address at Archimedesweg 4, 2333 CN Leiden, The Netherlands (?Janssen |
|
| May 17, 2021 |
Exhibit 99.1 Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update Data Readouts from Phase 1 AdCOVID? and ALT-801 Clinical Trials Expected in June Approximately $227 Million in Cash and Short-Term Investments to Advance Pipeline GAITHERSBURG, MD, - May 17, 2021 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 ALTIMMUNE, INC. |
|
| April 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 1, 2021 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 1, 2021 |
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™ EX-99.1 Exhibit 99.1 Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™ GAITHERSBURG, MD, April 1, 2021 — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy v |
|
| March 12, 2021 |
EX-99.1 Exhibit 99.1 Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility GAITHERSBURG, Maryland (USA) and Basel, Switzerland, March 12, 2021 — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has e |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2021 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Altimmune, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02155H200 (CUSIP Number) February 25, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 25, 2021 |
Exhibit 10.15 AMENDMENT NO. 5 TO SECOND RESTATED LICENSE AGREEMENT This Amendment No. 5 (?Amendment No. 5?) to the Second Restated License Agreement is made and entered into on the date of the last signature below by and between: Janssen Vaccines & Prevention B.V., a company under Dutch law with limited liability, with registered address at Archimedesweg 4, 2333 CN Leiden, The Netherlands (?Jansse |
|
| February 25, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File |
|
| February 25, 2021 |
Exhibit 21 SIGNIFICANT SUBSIDIARIES List of Subsidiaries Jurisdiction of Incorporation or Organization Altimmune, LLC (1) Delaware Altimmune UK, Limited (1) United Kingdom Spitfire Pharma, LLC (1) Delaware Altimmune AU Pty, Limited (1) Australia (1) Wholly owned subsidiary of the Company |
|
| February 25, 2021 |
Description of Registrant’s Securities Exhibit 4.10 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Altimmune, Inc. (?Altimmune? ?we,? or ?our?) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restat |
|
| February 25, 2021 |
Exhibit 99.1 Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun ALT-801 is Progressing Through the Phase 1 Clinical Trial Solidly Capitalized to Advance Pipeline Candidates with $216 Mill |
|
| February 25, 2021 |
Exhibit 99.2 Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID? - a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers Intranasal administration targets the virus at its point of entry and in a preclinical study induced local nasal mucosal i |
|
| February 25, 2021 |
Exhibit 1.1 ALTIMMUNE, INC. EQUITY DISTRIBUTION AGREEMENT February 25, 2021 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 B. RILEY SECURITIES, INC. 299 Park Avenue, 21st Floor New York, New York 10171 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Altimmune, |
|
| February 25, 2021 |
Exhibit 10.22 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 6 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicab |
|
| February 25, 2021 |
The date of this prospectus supplement is February 25, 2021. 424B5 1 d24591d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251858 PROSPECTUS SUPPLEMENT (to Prospectus dated January 11, 2021) Up to $125,000,000 Common Stock We have entered into an equity distribution agreement, dated February 25, 2021, or the Equity Distribution Agreement, with Piper Sandler & Co., Evercore Group L.L.C., and B. Riley Securities, Inc., |
|
| February 25, 2021 |
Exhibit 10.1 February 25, 2021 Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen: This letter agreement (the ?Agreement?) confirms the agreement of Altimmune, Inc., a Delaware corporation (the ?Company?), and the holders of the Common Stock listed on Schedule I attached hereto (the ?Stockholders?), pursuant to which the St |
|
| February 25, 2021 |
EX-4.1 2 alt-ex417.htm EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ]Original Issue Date: February 25, 2021 Altimmune, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assig |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 ALTIMMUNE, INC. |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32587 ALTIMMUNE, INC |
|
| February 16, 2021 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Altimmune, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 16, 2021 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its genera |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Altimmune, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Schedu |
|
| February 16, 2021 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| February 16, 2021 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Altimmune, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 8, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Altimmune, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02155H200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 7, 2021 |
CORRESP 1 filename1.htm Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 January 7, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Altimmune, Inc.: Registration Statement on Form S-3, filed December 31, 2020 (File No. 333-251858) Ladies and Gentlemen: Pursuant to Rul |
|
| December 31, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on December 31, 2020 Registration No. |
|
| December 31, 2020 |
Table of Contents Exhibit 4.2 ALTIMMUNE, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities Table of Contents Table of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form |
|
| December 31, 2020 |
Form of indenture for senior debt securities and the related form of senior debt security EX-4.1 Table of Contents Exhibit 4.1 ALTIMMUNE, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities Table of Contents Table of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 For |
|
| December 23, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2020 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission F |
|
| December 23, 2020 |
EX-99.1 Exhibit 99.1 Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial GAITHERSBURG, MD, December 23, 2020 — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s Investigational New Drug (IND) application for |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 ALTIMMUNE, INC. |
|
| November 9, 2020 |
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update Exhibit 99.1 Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update GAITHERSBURG, MD, November 9, 2020 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update. “2020 has been a transformational year for Altimmune as our pipeli |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 ALTIMM |
|
| November 9, 2020 |
Exhibit 10.2 ALTIMMUNE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Director Compensation Policy of Altimmune, Inc. (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpose stated a |
|
| November 9, 2020 |
Exhibit 10.1 AMENDMENT NO. 4 TO SECOND RESTATED LICENSE AGREEMENT This Amendment No. 4 (?Amendment No. 4?) to the Second Restated License Agreement (?License?) is made and entered into on the date of the last signature below by and between: Janssen Vaccines & Prevention B.V., a company under Dutch law with limited liability, with registered address at Archimedesweg 4, 2333 CN Leiden, The Netherlan |
|
| October 5, 2020 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| October 5, 2020 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| October 5, 2020 |
ALT / Altimmune, Inc. / D. E. SHAW & CO, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Altimmune, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 02155H200 (CUSIP Number) September 25, 2020 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Schedule is filed: ¨ Ru |
|
| September 25, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 ALTIMMUNE, INC. |
|
| September 24, 2020 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| September 24, 2020 |
ALT / Altimmune, Inc. / D. E. SHAW & CO, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Altimmune, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 02155H200 (CUSIP Number) September 14, 2020 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Schedule is filed: ¨ Ru |
|
| September 24, 2020 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| August 21, 2020 |
Form S-8 filed with the Securities and Exchange Commission on August 21, 2020 S-8 As filed with the Securities and Exchange Commission on August 21, 2020 Registration No. |
|
| August 21, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 ALTIMMUNE, |
|
| August 11, 2020 |
Exhibit 10.2 AMENDMENT NO. 2 TO SECOND RESTATED LICENSE AGREEMENT This Amendment No. 2 to the Second Restated License Agreement (this “Amendment No. 2”) is made and effective as of September 20, 2016 by and between Crucell Holland B.V., a corporation organized under the laws of the Netherlands, having offices at Archimedesweg 4-6, 2333 CN Leiden, the Netherlands (“CRUCELL”) and Altimmune, Inc., a |
|
| August 11, 2020 |
Exhibit 10.3 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. 3 TO SECOND RESTATED LICENSE AGREEMENT This Amendment No. 3 (“Amendment No. 3”) to the Second Restated License Agreement (“License”) is made and entered into on the date of the last si |
|
| August 11, 2020 |
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update Exhibit 99.1 Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update GAITHERSBURG, Maryland, August 11, 2020 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020 and provided a business update. “We are pleased with Altimmune’s progress during 2020 as we have l |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 ALTIMMUNE, INC. |
|
| July 16, 2020 |
EX-99.3 Exhibit 99.3 Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option GAITHERSBURG, Maryland, July 16, 2020 (GLOBE NEWSWIRE) – Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its previously announced underwritten public offering of 4,119,564 shares of its com |
|
| July 16, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 Altimmune, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-32587 20-2726770 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 16, 2020 |
EX-99.2 Exhibit 99.2 Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) – Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,369,564 shares of its common stock and, to certain invest |
|
| July 16, 2020 |
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants EX-99.1 Exhibit 99.1 Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) – Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certai |
|
| July 16, 2020 |
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2020 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 16, 2020 |
EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: July [ ], 2020 Altimmune, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitle |
|
| July 16, 2020 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION 3,369,564 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,630,436 shares of Common Stock ALTIMMUNE, INC. UNDERWRITING AGREEMENT July 13, 2020 JEFFERIES LLC EVERCORE GROUP L.L.C. PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd Stre |
|
| July 15, 2020 |
3,369,564 Shares of Common Stock Pre-Funded Warrants to Purchase 1,630,436 Shares of Common Stock 424B5 1 d30860d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230723 PROSPECTUS SUPPLEMENT (To prospectus dated April 12, 2019) 3,369,564 Shares of Common Stock Pre-Funded Warrants to Purchase 1,630,436 Shares of Common Stock We are offering an aggregate of 3,369,564 shares of our common stock, par value $0.0001 per share, and, to certain investors in lieu |
|
| July 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 13, 2020 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File |
|
| July 13, 2020 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230723 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| July 13, 2020 |
EX-99.1 Exhibit 99.1 Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVIDTM AdCOVID stimulated both strong serum neutralizing activity and potent mucosal immunity (IgA) in the respiratory tract GAITHERSBURG, MD, July 13, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmace |
|
| June 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Altimmune, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 02155H200 (CUSIP Number) Attention: General Counsel Venrock 3340 Hillview Avenue Palo Alto, California 94304 Name, Address and Telephone Number of Person Authorized to Receive No |
|
| June 1, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230723 AMENDMENT NO. 1 DATED June 1, 2020 To Prospectus Supplement dated March 27, 2020 (to Prospectus dated April 12, 2019) $50,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement, or this amendment, amends our prospectus supplement dated March 27, 2020, or the prospectus supplement. This amendment should |
|
| June 1, 2020 |
EX-99.1 Exhibit 99.1 Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19 • Clearance of IND application received from the U.S. FDA • Planned Phase 1/2 outpatient clinical trial will focus on patients with early SARS-CoV-2 infection • Placebo-controlled trial expected to commence in June with data readout e |
|
| June 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2020 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 1, 2020 |
ALT / Altimmune, Inc. / Venrock Healthcare Capital Partners Ii, L.p. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Altimmune, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 02155H200 (CUSIP Number) May 20, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 Altimmune, |
|
| May 13, 2020 |
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update Exhibit 99.1 Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update GAITHERSBURG, Maryland, May 13, 2020 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update. “Throughout 2020 we have put significant effort into developing our pipeline; from |
|
| May 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 ALTIMMUNE, INC. |
|
| May 12, 2020 |
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors EX-99.1 Exhibit 99.1 Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors GAITHERSBURG, Maryland, May 12, 2020 — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board of Directors. With Dr. Jorkasky’s appointment, the size of the board increased to eight members. “ |
|
| May 12, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2020 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 8, 2020 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 Altimmune, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32587 20-2726770 (State or other jurisdiction of incorporation) (Commission File |
